Jul 3, 2018

Mid-year drug price hikes are here

Drug capsules in production. Photo: Gerard Julien/AFP via Getty Images

Many pharmaceutical companies this week trotted out fresh price increases on existing products, a common mid-year occurrence that has not abated despite the Trump administration’s assertions that prices are coming down.

Why it matters: As we’ve reported over and over again, the pharmaceutical industry’s practices have not changed one iota even with the administration’s pricing blueprint, and drug companies still have every incentive to raise prices.

  • Pfizer raised list prices on more than 100 drugs as of July 1, David Crow of the Financial Times scooped.
  • Seattle Genetics and Sanofi also instituted mid-year hikes on some products, Meg Tirrell of CNBC reported.
  • Several other companies followed suit with large and small increases, others in the industry tell Axios.

Go deeper: The drug pricing war that leaves patients caught in the middle

Go deeper

Trump to install loyalist Ric Grenell as acting intelligence chief

Photo: Sylvain Gaboury/Patrick McMullan via Getty Images

President Trump confirmed in a tweet Wednesday night that he will install Richard Grenell, the current U.S. ambassador to Germany and a staunch defender of the president, as the acting director of national intelligence.

Why it matters: The role, which was originally vacated by Dan Coats in August 2019, is one of grave responsibility. As acting DNI, Grenell will be charged with overseeing and integrating the U.S. intelligence community and will advise the president and the National Security Council on intelligence matters that concern national security.

Go deeperArrowUpdated 16 mins ago - Politics & Policy

What to watch in the Nevada debate

Photo Illustration: Eniola Odetunde/Axios. Photos: Cengiz Yardages and Mario Tama/Getty Images

Michael Bloomberg's wealth will fuel rather than shield him from tests and attacks when he makes his Democratic primary debate debut on the stage tonight in Las Vegas.

The state of play: Bernie Sanders is still the front-runner. So the other candidates must weigh which of the two presents a bigger threat to their viability: Sanders, with his combined delegate, polling and grassroots momentum? Or Bloomberg, with his bottomless budget?

Go deeperArrowUpdated 22 mins ago - Politics & Policy

Axios Dashboard

Keep up with breaking news throughout the day — sign up for our alerts.